Company profile: Photocure
1.1 - Company Overview
Company description
- Provider of photodynamic specialty pharmaceuticals, including Hexvix/Cysview to improve bladder tumor detection and resection via Blue Light Cystoscopy, and Cevira, a photodynamic drug-device for non-surgical treatment of cervical HSIL; also supports patient registries and real-world evidence in bladder cancer. Norwegian-based.
Products and services
- Cevira: A photodynamic drug-device combination that non-surgically treats high-grade squamous intraepithelial lesions (HSIL) of the cervix, engineered to deliver therapy without excision
- Hexvix/Cysview: A blue-light-enabled drug that accumulates in bladder cancer cells, making them glow pink during cystoscopy to improve tumor detection and guide resection
- Patient Registries and Real-World Evidence: Registry-based initiatives that gather real-world bladder cancer treatment outcomes to enhance clinical practice and patient care.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Photocure
Spirogen
HQ: United Kingdom
Website
- Description: Provider of novel, sequence-selective DNA minor groove-binding molecules and proprietary pyrrolobenzodiazepine (PBD) technology, including PBD-based ADC payloads and PBD dimers that cross-link DNA to block replication and kill cancer stem cells. Offers licensing of PBD technology and research collaborations/partnerships to develop PBD-based ADCs designed to deliver potent anticancer agents to cancer cells for different cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spirogen company profile →
Normunity
HQ: United States
Website
- Description: Provider of precision immuno-oncology medicines focused on immune normalizers—novel cancer immunotherapies that restore normal immune responses. Includes the Chen Lab Discovery Platform to identify and validate novel targets and Normunity Drug Development to create monoclonal antibodies based on these discoveries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normunity company profile →
Bicara Therapeutics
HQ: United States
Website
- Description: Provider of dual-action cancer therapies combining targeted treatments with tumor modulators. Offers BCA101, a dual-action bifunctional antibody that inhibits EGFR and disables TGF-β at the tumor site, in clinical trials across multiple cancer types; and BCA356, a bispecific antibody targeting CAIX conjugated to attenuated IL-12, with pre-clinical efficacy and potential for limited systemic toxicity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bicara Therapeutics company profile →
BioVex
HQ: United Kingdom
Website
- Description: Provider of biological treatments for cancer and infectious diseases, focused on development and commercialization. Its cancer program includes OncoVEXGM-CSF, an oncolytic vaccine/cancer-destroying virus that replicates and spreads within solid tumors, causing tumor destruction, and it advances biological treatments for the prevention of infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVex company profile →
T3 Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Photocure
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Photocure
2.2 - Growth funds investing in similar companies to Photocure
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Photocure
4.2 - Public trading comparable groups for Photocure
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →